Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases
- PMID: 11981314
- DOI: 10.1097/00002281-200205000-00002
Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases
Abstract
Tumor necrosis factor-alpha (TNF-alpha) antagonists have rapidly emerged as a valuable class of antirheumatic agents. Etanercept, a dimerized version of the soluble tumor necrosis factor receptor II, and infliximab, a chimeric anti-TNF-alpha monoclonal antibody, are currently approved for the treatment of rheumatoid arthritis (RA) based on their proven beneficial effects in clinical trials. New insights into the role of TNF-alpha in disease pathogenesis have expanded our understanding about the possible mechanisms by which these agents reduce synovial inflammation and inhibit bone and cartilage degradation. The enlarging safety experience has revealed growing concerns about TNF-alpha inhibition and increased risk for opportunistic infection, most notably the reactivation of latent Mycobacterium tuberculosis infection. Recent recommendations have addressed this risk by calling for pretreatment screening for previous exposure to tuberculosis. The success of etanercept and infliximab therapy for RA has prompted the development of other TNF-alpha antagonists and extended the investigation of this therapeutic approach to other inflammatory diseases. TNF-alpha antagonists promise to shape the care of RA and other rheumatic diseases for many years to come.
Similar articles
-
Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.Clin Immunol. 2002 Jun;103(3 Pt 1):231-42. doi: 10.1006/clim.2002.5191. Clin Immunol. 2002. PMID: 12173297 Review.
-
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.Arthritis Rheum. 2005 Jun;52(6):1766-72. doi: 10.1002/art.21043. Arthritis Rheum. 2005. PMID: 15934089
-
[New drugs and treatment strategies for rheumatoid arthritis].Recenti Prog Med. 2003 Sep;94(9):361-79. Recenti Prog Med. 2003. PMID: 12942798 Review. Italian.
-
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x. Int J Rheum Dis. 2009. PMID: 20374328
-
[Autoimmune aspects of treatment with TNF-alpha inhibitors].Postepy Hig Med Dosw (Online). 2007 Aug 28;61:478-84. Postepy Hig Med Dosw (Online). 2007. PMID: 17786135 Review. Polish.
Cited by
-
Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis.Clin Exp Immunol. 2012 May;168(2):165-77. doi: 10.1111/j.1365-2249.2012.04567.x. Clin Exp Immunol. 2012. PMID: 22471277 Free PMC article.
-
Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection.PLoS One. 2010 Jan 13;5(1):e8644. doi: 10.1371/journal.pone.0008644. PLoS One. 2010. PMID: 20072623 Free PMC article.
-
Antithetical effects of hemicellulase-treated Agaricus blazei on the maturation of murine bone-marrow-derived dendritic cells.Immunology. 2005 Mar;114(3):397-409. doi: 10.1111/j.1365-2567.2004.02106.x. Immunology. 2005. PMID: 15720441 Free PMC article.
-
Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.Ann Rheum Dis. 2003 Nov;62(11):1078-82. doi: 10.1136/ard.62.11.1078. Ann Rheum Dis. 2003. PMID: 14583571 Free PMC article.
-
A systematic assessment of linking gene expression with genetic variants for prioritizing candidate targets.Pac Symp Biocomput. 2015;20:383-94. Pac Symp Biocomput. 2015. PMID: 25592598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
